Summit Therapeutics

Yahoo Finance • 11 days ago

Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) and set a $1... Full story

Yahoo Finance • 17 days ago

Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now?

Key Points In a previous clinical trial, Summit's cancer drug ivonescimab showed it was more effective than Keytruda. The excitement propelled Summit's stock to a valuation that at one point reached $27 billion. The company doesn't genera... Full story

Yahoo Finance • 20 days ago

2 Monster Stocks in the Making to Buy and Hold

Key Points SoFi Technologies could become the dominant banking model in the future. Summit Therapeutics is developing a drug with incredible sales potential. 10 stocks we like better than SoFi Technologies › It's not possible to go back... Full story

Yahoo Finance • 2 months ago

Apple foldable iPad may be delayed amid development snag: report

[Close Up Of Business Colleagues Using Digital Tablet Together] Tom Werner * A foldable version of the iPad may be delayed, as Apple (NASDAQ:AAPL [https://seekingalpha.com/symbol/AAPL]) has reportedly hit some snags in developing the ta... Full story

Yahoo Finance • 2 months ago

SA analyst upgrades/downgrades: TSLA, MSFT, AAPL, SMMT

[Stock market trading, financial data graph chart, data visualization, Business arrow graph chart] Rasi Bhadramani Recent Seeking Alpha analyst actions have revealed significant shifts in market outlooks for key technology and healthcare... Full story

Yahoo Finance • 2 months ago

Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab

​Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 17, Summit Therapeutics Inc. (NASDAQ:SMMT) announced the expansion of its Phase 3 clinical development program called HARMONi-G... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: Apple, Cleveland-Cliffs, Oracle, KLA, Tempus AI and more

Check out the companies making the biggest moves midday: Apple — The Tim Cook-led company climbed 4% after the iPhone 17 series outsold the iPhone 16 series in China and the U.S. in the first 10 days of availability, according to Counterpo... Full story

Yahoo Finance • 2 months ago

Stock market today: Dow, S&P 500, Nasdaq rise amid trade-war lull, with flurry of earnings on deck

US stocks stepped higher on Monday as Wall Street kicked off packed week full of high-profile earnings and a delayed release of key inflation data. The Dow Jones Industrial Average (^DJI) nudged up roughly 0.4%, while the S&P 500 (^GSPC)... Full story

Yahoo Finance • 2 months ago

Summit Therapeutics Non-GAAP EPS of -$0.13 misses by $0.07

* Summit Therapeutics press release [https://seekingalpha.com/pr/20271273-summit-therapeutics-reports-financial-results-and-operational-progress-for-the-third-quarter] (NASDAQ:SMMT [https://seekingalpha.com/symbol/SMMT]): Q3 Non-GAAP EPS... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Cleveland-Cliffs (CLF [https://seekingalpha.com/symbol/CLF]) * Dynex Capital (DX [https://seekingalpha.com/symbol/DX]) * Delcath Systems (DCTH [https://seekingalpha.com/sy... Full story

Yahoo Finance • 2 months ago

UK’s automotive remanufacturing industry could drive economy: SMMT

The Society of Motor Manufacturers and Traders (SMMT) has released a report indicating that the UK’s automotive remanufacturing sector presents an opportunity for economic advancement and enhanced resource self-reliance. The report unders... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at ne... Full story

Yahoo Finance • 3 months ago

Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Summit Therapeutics Inc. stands amongst them. Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical company focused on non-small cel... Full story

Yahoo Finance • 3 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. investors  ("Summit" or the "Company") (NASDAQ: SMMT) investors that the firm has initiated an investigation into possible securities f... Full story

Yahoo Finance • 3 months ago

QuantumScape rallies as Seeking Alpha analyst pitches the upside

[Financial advisor interacts with a digital interface displaying machine learning data insights.] QuantumScape Corporation (NYSE:QS [https://seekingalpha.com/symbol/QS]) rallied in morning trading on Thursday as it took back ground lost o... Full story

Yahoo Finance • 3 months ago

Rapport Therapeutics prices $250M stock at $26 per share

* Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) priced [https://seekingalpha.com/pr/20227241-rapport-announces-pricing-of-public-offering-of-common-stock] an underwritten public offering of 9.62M shares at a p... Full story

Yahoo Finance • 3 months ago

Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 3, Bradley Canino from Guggenheim initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT) with a Buy... Full story

Yahoo Finance • 3 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The original press release, distributed Tuesday, September 9, 2025, incorrectly stated that a lawsuit was filed against Summit Therapeutics, in the headline and body of the release. The Por... Full story

Yahoo Finance • 3 months ago

Summit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT) i... Full story

Yahoo Finance • 3 months ago

S&P Futures Tick Higher Ahead of U.S. Payrolls Revisions

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are trending up +0.17% this morning, buoyed by hopes for multiple interest rate cuts from the Federal Reserve this year, while investors await an annu... Full story